FDA grants orphan drug designation to natural killer cell therapy for multiple myeloma

The FDA granted orphan drug designation to CellProtect, a modified natural killer cell therapy for the treatment of patients with multiple myeloma, according to the agent’s manufacturer.

CellProtect (XNK Therapeutics) is an investigational autologous cell therapy produced through ex vivo expansion and activation of natural killer cells from peripheral blood of patients with cancer.

The technology used to produce the therapy is based on natural killer cell research performed at Karolinska Institute in Stockholm. The manufacturing process takes a little less than 3 weeks, according to the manufacturer.

“Obtaining an [orphan drug designation] by the FDA is a significant milestone for XNK and our goal of taking [this] drug candidate to the next level,” Johan Liwing, CEO of XNK Therapeutics, said in a press release. “This is the starting point for us to expand clinical development into the most important market globally for cancer treatment.”

Researchers tested CellProtect in the phase 1/phase 2 ACP-001 trial, results of which were presented at this year’s European Hematology Association Annual Meeting. The trial evaluated CellProtect as consolidation treatment after high-dose stem cell transplantation among patients with newly diagnosed multiple myeloma.

To Read the Complete Article at Healio, Click Here

Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained within the article. Content available through the site may contain links and information to other websites. Links from BioPharma Global to third-party sites do not constitute an endorsement by BioPharma Global of the mentioned parties.

BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.

Stock image by @vitanovski from Depositphotos